Today there are new developments in the battle against severe chronic pancreatitis as TikoMed AB and Baylor Research Institute (BRI) announce they are teaming up for Phase II clinical trials involving the former’s IBsolvMIR® product. BRI, which is Baylor Health Care System’s research division, has created a new therapy that will used in the treatment of chronic pancreatitis.
According to an article on PharmaLive, it is thought that IBsolvMIR will be helpful in enhancing the results of said therapy by “improving the survival of transplanted cells by inhibiting a destructive immunological reaction (IBMIR) and through stimulation of growth factors.” The “Attenuating Instant Blood-Mediated Inflammatory Reaction in Autologous Islet Transplantation” BRI study will be overseen by Principal Investigator Marlon F. Levy, M.D., and will seek to determine and “document efficacy, safety and tolerability of IBsolvMIR in auto islet transplants for patients with chronic pancreatitis.”
“Entering into a phase II study in the U.S. is a significant step in the clinical development of IBsolvMIR,” TikoMed’s CEO Anders Waas proclaimed after the announcement. “It strengthens TikoMed’s competitive position in partnership discussions and for commercialization for IBsolvMIR in the U.S.”
Islet cell transplants can be used in patients with Type 1 diabetes or the aforementioned chronic pancreatitis, and the therapy developed at Baylor University to process cells for transplant was the first in Texas to receive FDA approval. In the case of treating pancreatitis, the cell transplants are meant to reduce pain without causing diabetes in patients. The Chairman of TikoMed, Adam Bruce, spoke of the necessity of companies like his to build reciprocal relationships with institutions like Baylor in order to come up with the best possible ways to combat serious diseases and afflictions. For his part, Baylor’s Dr. Levy expressed his team’s excitement at the prospect of working in tandem with TikoMed to try and improve the lives of those who need such cell transplants.